CPA
CORT icon

Clear Perspective Advisors’s Corcept Therapeutics CORT Stock Holding History

Clear Perspective Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-550
Closed -$11K – 467
2017
Q3 		$11K Hold
550
– – 0.01% 327
2017
Q2 		$6K Buy
+550
New +$5.98K 0.01% 376

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Clear Perspective Advisors's CORT Position: Q4 2017 in Review

Clear Perspective Advisors sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 550 shares — an estimated $11K sold.

Clear Perspective Advisors first reported a position in CORT in Q2 2017 and held it in 2 quarters. The position peaked at $11K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Clear Perspective Advisors reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Clear Perspective Advisors sold 550 Corcept Therapeutics shares in Q4 2017, an estimated $11K.
  • Clear Perspective Advisors first reported a position in Corcept Therapeutics in Q2 2017 and held it in 2 quarters.
  • Clear Perspective Advisors's Corcept Therapeutics position peaked at $11K in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Clear Perspective Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.